Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EntreMed appoints interim CEO

This article was originally published in Scrip

Executive Summary

The clinical-stage cancer company has appointed Dr Ken Ren as interim CEO, effective 2 April 2012. Dr Ren has years of experience in conducting global trials for multi-national pharmaceutical and biotech companies, and was also the founder and key manager of several private companies operating in the US and China in pharmaceutical development and services. The new appointment comes just months after the company announced that it had appointed Dr Wei-Wu He executive chair, and Dr Tak Mak to its board of directors.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC016923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel